title: Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation.
abstract: We compared the influence of induction therapy on 5-year patient and graft survival as well as on renal function in 100 kidney graft recipients at low immunological risk treated with antilymphocyte globulin (n = 50) versus anti-IL-2R monoclonal antibody (n = 50) in a prospective multicenter study. Long-term immunosuppressive treatment included cyclosporine, mycophenolate mofetil, and a short course of steroids in all patients. Five year graft (86% vs 86%) and patient (94% vs 94%) survivals were identical in both study arms. Moreover, neither serum creatinine or proteinuria were significantly different between the two groups. Our results showed that the choice of the induction therapy seemed to not have a major impact on long-term outcomes among renal recipients at low immunological risk.
authors.affiliation: Departments of Nephrology and Clinical Immunology, CHU Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37044 Tours cedex 9, France. a.alnajjar@chu-tours.fr
authors.forename: A
authors.initials: A
authors.lastname: Al Najjar
authors.forename: I
authors.initials: I
authors.lastname: Etienne
authors.forename: P
authors.initials: P
authors.lastname: Le Pogamp
authors.forename: F
authors.initials: F
authors.lastname: Bridoux
authors.forename: Y
authors.initials: Y
authors.lastname: Le Meur
authors.forename: O
authors.initials: O
authors.lastname: Toupance
authors.forename: C
authors.initials: C
authors.lastname: Mousson
authors.forename: S
authors.initials: S
authors.lastname: Caillard
authors.forename: B
authors.initials: B
authors.lastname: Hurault de Ligny
authors.forename: J F
authors.initials: JF
authors.lastname: Marlière
authors.forename: Y
authors.initials: Y
authors.lastname: Lebranchu
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D000077552:Basiliximab; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; C512542:thymoglobulin